Brief

On March 15, 2024, the National Health Surveillance Agency (Anvisa) concluded its project "Monitoring and Periodic Analysis of Advanced Therapy Products: Reevaluation of Benefit-Risk Profile and Social Transparency". The agency monitored five advanced therapy products registered since 2020, analyzing their efficacy and safety.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies